From Batch to the Semi-Continuous Flow Hydrogenation of pNB, pNZ-Protected Meropenem
Pharmaceutics · 23.04.2023 · 15 (5) · 1322
DOI: 10.3390/pharmaceutics15051322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 23.04.2023. Verfasst von Marziale Comito und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Meropenem is currently the most common carbapenem in clinical applications. Industrially, the final synthetic step is characterized by a heterogeneous catalytic hydrogenation in batch mode with hydrogen and Pd/C. The required high-quality standard is very difficult to meet and specific conditions are required to remove both protecting groups [i.e., p-nitrobenzyl (pNB) and p-nitrobenzyloxycarbonyl (pNZ)] simultaneously. The three-phase gas–liquid–solid system makes this step difficult and unsafe. The introduction of new technologies for small-molecule synthesis in recent years has opened up new landscapes in process chemistry. In this context, we have investigated meropenem hydrogenolysis using microwave (MW)-assisted flow chemistry for use as a new technology with industrial prospects. The reaction parameters (catalyst amount, T, P, residence time, flow rate) in the move from the batch process to semi-continuous flow were investigated under mild conditions to determine their influence on the reaction rate. The optimization of the residence time (840 s) and the number of cycles (4) allowed us to develop a novel protocol that halves the reaction time compared to batch production (14 min vs. 30 min) while maintaining the same product quality. The increase in productivity using this semi-continuous flow technique compensates for the slightly lower yield (70% vs. 74%) obtained in batch mode.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.
- Research and Development, ACS Dobfar SpA, Via Paullo 9, 20067 Tribiano, Italy.
- Dipartimento di Scienza e Alta Tecnologia, University of Insubria, Via Valleggio 9, 22100 Como, Italy.
ORCID-Profile: Marziale Comito, Silvia Tagliapietra, Angelo Maspero, Giancarlo Cravotto
Zitieren
APA
Comito, M., Monguzzi, R., Tagliapietra, S., Maspero, A., Palmisano, G., & Cravotto, G. (2023). From Batch to the Semi-Continuous Flow Hydrogenation of pNB, pNZ-Protected Meropenem. Pharmaceutics, 15(5), 1322. https://doi.org/10.3390/pharmaceutics15051322
Vancouver
Comito M, Monguzzi R, Tagliapietra S, Maspero A, Palmisano G, Cravotto G. From Batch to the Semi-Continuous Flow Hydrogenation of pNB, pNZ-Protected Meropenem. Pharmaceutics. 2023;15(5):1322. doi:10.3390/pharmaceutics15051322
BibTeX
@article{Comito2023,
author = {Comito, Marziale and Monguzzi, Riccardo and Tagliapietra, Silvia and Maspero, Angelo and Palmisano, Giovanni and Cravotto, Giancarlo},
title = {From Batch to the Semi-Continuous Flow Hydrogenation of pNB, pNZ-Protected Meropenem},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {5},
pages = {1322},
doi = {10.3390/pharmaceutics15051322}
}
EUVIMED